CD22 CAR-T细胞治疗后HLH样表现作为CRS变异型的特征分析
该研究在59例接受CD22 CAR-T细胞输注的患者中,描述21例(40.4%)CRS患者出现carHLH的临床表现与时机,并探索相关危险因素。carHLH表现为高铁蛋白血症、高甘油三酯血症、低纤维蛋白原血症等,与输注前NK细胞减少及骨髓T细胞:NK细胞比值升高相关,且HLH相关炎性细胞因子持续升高。
要点
- CD22 CAR-T后carHLH是CRS变异型,52例CRS中21例(40.4%)发生。
- carHLH特征包括高铁蛋白、高甘油三酯、低纤维蛋白原、凝血病和转氨酶升高。
- 输注前NK细胞减少和骨髓T:NK比值高与carHLH风险相关。
核心结论
- carHLH是CD22 CAR-T后CRS的变异型,其临床表现和免疫表型与继发性HLH重叠,需考虑替代管理框架。
研究设计与样本
- 回顾性分析59例接受CD22 CAR-T细胞输注的患者,其中52例发生CRS。
主要发现
- 52例CRS患者中21例(40.4%)发生carHLH。
- carHLH临床特征包括高铁蛋白血症、高甘油三酯血症、低纤维蛋白原血症、凝血病、肝转氨酶升高、高胆红素血症、严重中性粒细胞减少、乳酸脱氢酶升高,偶见噬血现象。
- carHLH与输注前NK细胞减少及骨髓T细胞:NK细胞比值升高相关,CAR-T扩增后差异进一步放大。
- carHLH患者HLH相关炎性细胞因子持续升高,而无carHLH者下降。
临床怎么用
- 接受CD22 CAR-T治疗的患者应监测carHLH相关临床表现,尤其存在输注前NK细胞减少或骨髓T:NK比值升高者。
局限性
- 研究样本量有限(59例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell toxicities resembling hemophagocytic lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release syndrome (CRS). As a variant of conventional CRS, a comprehensive characterization of CAR T-cell-associated HLH (carHLH) and investigations into associated risk factors are lacking. In the context of 59 patients infused with CD22 CAR T cells where a substantial proportion developed carHLH, we comprehensively describe the manifestations and timing of carHLH as a CRS variant and explore factors associated with this clinical profile. Among 52 subjects with CRS, 21 (40.4%) developed carHLH. Clinical features of carHLH included hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, coagulopathy, hepatic transaminitis, hyperbilirubinemia, severe neutropenia, elevated lactate dehydrogenase, and occasionally hemophagocytosis. Development of carHLH was associated with preinfusion natural killer(NK) cell lymphopenia and higher bone marrow T-cell:NK cell ratio, which was further amplified with CAR T-cell expansion. Following CRS, more robust CAR T-cell and CD8 T-cell expansion in concert with pronounced NK cell lymphopenia amplified preinfusion differences in those with carHLH without evidence for defects in NK cell mediated cytotoxicity. CarHLH was further characterized by persistent elevation of HLH-associated inflammatory cytokines, which contrasted with declining levels in those without carHLH. In the setting of CAR T-cell mediated expansion, clinical manifestations and immunophenotypic profiling in those with carHLH overlap with features of secondary HLH, prompting consideration of an alternative framework for identification and management of this toxicity profile to optimize outcomes following CAR T-cell infusion.
引用
- Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021. PMID: 34525183. doi:10.1182/blood.2021011898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。